EULAR 2024

Difference in axial involvement in axSpA and axPsA

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

Tapering or even stopping TNF inhibitors in pts. with…

JAK inhibitors in GCA - a good opportunity?

Handling cardiovascular risks in RA

Factors associated with spinal progression in axSpA

Sooner or later - when therapy with biologics?

Treat-to-target approach to induce sustained clinical…

Treat-to-target in axSpA - a long way to go!

Minimal spinal radiographic progression with…

Uterine inflammation in the pathogenesis in axSpA

What advances the radiographic progression? IL-17A vs.…

Neuroinflammation as possible cause of intestinal…

Treat-to-target bei der axSpA - a long way to go!

Vermeidung von Überdiagnose bei axSpA

Früher oder später - wann Therapie mit Biologika?

Approccio treat-to-target per indurre una remissione…

Ruolo della neuroinfiammazione della patogensi…

Minimale Röntgenprogression der Wirbelsäule unter…

Was treibt die Röntgenprogression an? IL-17A vs. TNF…

Tyk2 inhibition in PsA - a new opportunity?

Subclinical PsA - where is the border?

IL-17 inhibition & new molecules

A new injection for knee osteoarthritis

A lot of steroids always help - no matter the…

Sonelokimab, a new molecule for IL-17A & IL-17F…

A mouse model for PsA and PsO!

12-weeks results from the PRO-SPIRIT study

Post-hoc analysis on severe disease activity in PsA

The difficult cases in PsA

Treatment strategy in early PsA - TnF inhibitors or…

Small molecules with a better enthesitis efficacy - new…

Managing comorbidities in PsA

The JAK family is growing. Another Tyk2 inhibitor: safe…

Early prediction by FAPI-PET in PsA

Which treatment to prevent PsA from PsO?

Sonelokimab, ein neues Molekül zur IL-17A- &…

Risultati a 12 settimane dello studio di Real World…

Rhumatisme psoriasique débutant : anti TNF ou pas?

Kleine Moleküle mit besserer Enthesitiswirkung - neue…

Frühe Prädiktion durch FAPI-PET bei PsA

Quel traitement pour prévenir l’évolution du psoriasis…

Viel Kortison hilft immer - Begleittherapie egal...

Valutazione della risposta a due anni di trattamento…

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor:…

Handling cardiovascular risks in RA

Tapering or even stopping TNF inhibitors in pts. with…

Deeper B-cell depletion

Tapering of TNF Inhibitors in RA Patients with…

Statins in RA - who benefits?

Real-world data on safety of etanercept biosimilar

Anti-citrullinated protein antibody (ACPA) does not…

Good news in RA

Potential new treatment class in RA

New JAK inhibitor tested in a Phase III trial in China

ARCTIC REWIND - Tapering not recommended in patients on…

Debate on therapeutic drug monitoring

A model to predict progression from palindromic…

Abatacept vs adalimumab in dual seropositive RA…

Debate on regulatory safety measures for JAKies based…

Debatt om regulatoriske krav om sikkerhet ved bruk av…

En ny JAK hemmer undersøkt i en fase III studie I Kina

Abatacept vs adalimumab en pacientes con AR doble…

Reducción y suspensión de los inhibidores del TNF en…

Keine neuen Safety-Signale aus der JAK-POT Studie

Un modelo para predecir la progresión del reumatismo…

ARCTIC REWIND – dosereduksjon og seponering anbefales…

Debatt om bruk av therapeutic drug monitoring (TDM,…

The role of rheumatoid factor from early to late

Holistic view on multidisciplinary care in rheumatology

Daratumumab in SLE